Enlitic Inc.

ENL.ASX

Health Care

Enlitic is a software development company that uses artificial intelligence to develop software products that manage medical imaging data in radiology (such as MRI, CT, X-ray and ultrasound images) and licences such products to healthcare providers.

Market Data

Price

$0.008

-0.1%
Market Cap

$6.7M

P/E Ratio

-100000.0x

EPS

$-0.026

Div. Yield

0.00%

52-Week Change

-0.7%

Latest Earnings

Appendix 4E & 2025 Annual Report

27 February 2026

Revenue
$3.80
+251.9% YoY
NPAT
-$13.37
+12.2% YoY

Enlitic, Inc. reported FY2025 revenue of US$3.8M, up 251.9% year-on-year, primarily driven by a full 12-month contribution from the Laitek acquisition (completed October 2024) versus a partial period in 2024. The net loss narrowed 12.2% to US$13.4M as operating costs remained broadly flat at ~US$17.1M, reflecting cost discipline and integration efficiencies. The company is transitioning from platform development to commercial execution, with key OEM partnerships signed (GE HealthCare, Philips, Fuji, Infinitt), though going concern risk remains material given ongoing cash burn and reliance on external funding. Key points: Revenue surged 251.9% to US$3.8M, reflecting first full year of Laitek operations acquired in October 2024.; Net loss narrowed 12.2% to US$13.4M despite broadly flat operating costs (~US$17.1M), demonstrating cost discipline.; Binding MOU signed with GE HealthCare in May 2025 targeting US$3–6M/year in migration services over 5 years; US$2M advance payment received July 2025.

Recent Announcements

27 Feb 2026 Actual Results Neutral

Appendix 4E & 2025 Annual Report

Enlitic, Inc. reported FY2025 revenue of US$3.8M, up 251.9% year-on-year, primarily driven by a full 12-month contribution from the Laitek acquisition (completed October 2024) versus a partial period in 2024. The net loss narrowed 12.2% to US$13.4M as operating costs remained broadly flat at ~US$17.1M, reflecting cost discipline and integration efficiencies. The company is transitioning from platform development to commercial execution, with key OEM partnerships signed (GE HealthCare, Philips, Fuji, Infinitt), though going concern risk remains material given ongoing cash burn and reliance on external funding. Key points: Revenue surged 251.9% to US$3.8M, reflecting first full year of Laitek operations acquired in October 2024.; Net loss narrowed 12.2% to US$13.4M despite broadly flat operating costs (~US$17.1M), demonstrating cost discipline.; Binding MOU signed with GE HealthCare in May 2025 targeting US$3–6M/year in migration services over 5 years; US$2M advance payment received July 2025.

Get real-time alerts for ENL

Receive AI-powered earnings summaries and instant notifications when Enlitic Inc. releases results.

Register Free